Sapio Sciences has entered a strategic partnership with Ultima Genomics to link its lab informatics platform with Ultima’s high-throughput sequencing system, aiming to make multi-omics workflows more accessible and less fragmented.

The deal brings together Ultima’s focus on lowering the cost of sequencing with Sapio’s data management, automation and analytics tools. The companies said the combination is designed to help laboratories move away from multiple costly assays and piecemeal systems when working across genomics, transcriptomics, proteomics and other omics layers.

Ultima has developed a sequencing architecture intended to scale beyond conventional technologies and to reduce the cost per sample in high-throughput projects. The company argues that this makes it possible to study more than DNA sequences alone, including epigenomic changes that can play an early role in cancer and other diseases.

Sapio, based in Baltimore, provides a lab informatics platform that uses AI to support automation, workflow management and compliance. The company said its integration with Ultima will ensure full data provenance, giving research and clinical users traceability from sequencing through to analysis.

Gilad Almogy, chief executive and founder of Ultima Genomics, said: “Partnering with Sapio Sciences aligns with our goals to enable leading sequencing labs and make genomic information more scalable. By integrating our high-throughput, low-cost sequencing platform with Sapio’s AI-powered lab informatics platform, we’re enabling a seamless, scalable solution for multi-omics research and clinical genomics.”

For researchers, the companies highlighted four expected benefits: lower per-sample costs, faster discovery cycles through AI-driven analytics, improved traceability to meet compliance demands, and a unified environment that avoids fragmented assays.

Andrew Wyatt, chief growth officer at Sapio, added that the link with Ultima will help laboratories manage growing volumes of omics data and “scale without compromising quality or compliance.”

The partnership also fits within Sapio’s wider partner programme, which includes technology, services and reseller ecosystems. Through these arrangements, Sapio aims to extend the reach of its platform across hardware and cloud providers, advisory groups and value-added resellers.

With sequencing costs under pressure and demand for deeper biological insight increasing, both companies are pitching the partnership as a step towards more routine use of multi-omics in research and clinical settings.